Hypoglycemic composition containing Chinese chestnut resistant starch as well as preparation method and application of hypoglycemic composition

Abstract

The invention discloses a hypoglycemic composition containing Chinese chestnut resistant starch as well as a preparation method and application of the hypoglycemic composition. Belongs to the technical field of blood sugar reduction. The composition comprises the following components in parts by mass: 30-40 parts of Chinese chestnut resistant starch, 10-20 parts of Chinese yam, 10-20 parts of pearl barley and 2-10 parts of platycodon grandiflorum. Compared with the prior art, the composition disclosed by the invention has the beneficial effects that the prepared composition has a remarkable hypoglycemic effect, the raw materials are safe and green, and the composition has relatively high application and development values.

Description

Technical Field

[0001] The present invention relates to the technical field of hypoglycemic agents, and more particularly to a hypoglycemic agent containing chestnut resistant starch, and a preparation method and application thereof. Background Art

[0002] Insulin resistance and pancreatic β-cell dysfunction are important features of T2DM, leading to persistent hyperglycemia in people with T2DM. Although existing treatments, such as oral hypoglycemic drugs and insulin, can alleviate some complications of T2DM, there is still a need to find effective ways to control this chronic disease.

[0003] Dietary and lifestyle changes may delay the onset of T2DM. In addition, the consumption of healthy natural products with certain hypoglycemic effects may serve as a long-term treatment for T2DM.

[0004] Chestnut is the fruit of the plant Castanea genus of the Fagaceae family. It is a food and medicine with high nutritional value. It contains a variety of nutrients such as starch, protein and lipids, and is rich in bioactive substances such as polyphenols, flavonoids and polysaccharides.

[0005] At present, the relevant research on the nutritional active ingredients in chestnut kernels focuses on chestnut starch, protein, polyphenols, dietary fiber, mineral elements and vitamins, and there are no reports on the research on the hypoglycemic function of chestnut resistant starch. Summary of the invention

[0006] In view of this, the present invention provides a blood sugar lowering composition containing chestnut resistant starch, and a preparation method and application thereof.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] A hypoglycemic composition containing chestnut resistant starch comprises the following components in parts by weight: 30-40 parts of chestnut resistant starch, 10-20 parts of yam, 10-20 parts of coix seeds and 2-10 parts of platycodon.

[0009] Beneficial effects achieved:

[0010] Chestnut resistant starch is sweet and has the effect of lowering blood sugar.

[0011] Yam is sweet in taste, nourishes the kidney qi, strengthens the spleen and stomach, stops diarrhea, resolves phlegm and moisturizes the skin and hair.

[0012] Job's tears has a sweet and mild taste, and can promote diuresis and eliminate dampness, strengthen the spleen and stop diarrhea, eliminate numbness, discharge pus, detoxify and disperse nodules.

[0013] Platycodon grandiflorum tastes bitter and spicy, is neutral in nature, and can clear the lungs, relieve sore throat, eliminate phlegm, and discharge pus.

[0014] All raw materials are of medicinal and edible homology and have no mutual medicinal antagonism.

[0015] The resulting formula is particularly mild and has a wide range of applicability.

[0016] Furthermore, the invention comprises the following components in parts by weight: 36-40 parts of chestnut resistant starch, 15-16 parts of yam, 15-16 parts of coix seeds and 6-8 parts of platycodon.

[0017] Furthermore, the invention comprises the following components in parts by weight: 36 parts of chestnut resistant starch, 15 parts of yam, 15 parts of coix seeds and 6 parts of platycodon.

[0018] Furthermore, the composition includes the following components in parts by weight: 40 parts of chestnut resistant starch, 16 parts of yam, 16 parts of coix seeds and 8 parts of platycodon.

[0019] Furthermore, the chestnut resistant starch accounts for ≥40% of the total mass ratio, and the total amount of yam and coix seed accounts for ≥10% of the total mass ratio.

[0020] The preparation method of the above composition comprises the following steps: drying, crushing, sieving, mixing and sieving the raw materials, and pressing them with a tablet press.

[0021] Furthermore, the screening is through an 80-mesh sieve.

[0022] Furthermore, the specific operation of the tablet press is: using a circular mold with a diameter of 10 mm, keeping the pressure and thickness constant, pressing in the tablet press, and the tablet weight is 0.36 g.

[0023] The application of the above composition in the preparation of hypoglycemic drugs.

[0024] It can be seen from the above technical solution that, compared with the prior art, the beneficial effects achieved by the present invention are:

[0025] The present invention prepares compressed tablets by combining chestnut resistant starch with significant blood sugar lowering effect with other ingredients with blood sugar lowering effect, exerting a synergistic effect and being able to significantly reduce the blood sugar index of diabetic patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0027] Figure 1 The attached figure is an X-ray diffraction diagram of the chestnut resistant starch of the present invention. DETAILED DESCRIPTION

[0028] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0029] The drugs required for the present invention are conventional experimental drugs, which are purchased from commercial channels; the experimental methods not mentioned are conventional experimental methods and will not be described in detail here.

[0030] Example 1

[0031] Preparation method of chestnut resistant starch:

[0032] A chestnut starch suspension with a mass fraction of 35% was placed in a high pressure steam cooker and autoclaved at 1.1 bar for 30 minutes at 120°C. The treated starch suspension was cooled to 50°C and then adjusted to a pH of 5. Pullulanase was added and enzymolysis was performed at 45°C for 7 hours. The reaction tube was then incubated in a 100°C water bath for 15 minutes to inactivate the enzyme. The reaction starch suspension was incubated at a constant temperature of 4°C for 24 hours, then dried at 40°C for 24 hours, and ground through an 80-mesh sieve.

[0033] X-ray diffraction pattern of chestnut resistant starch Figure 1 shown.

[0034] A hypoglycemic compressed tablet containing chestnut resistant starch, the preparation method of which is as follows:

[0035] (1) Dry chestnut resistant starch, yam, coix seed and platycodon grandiflorum at 50°C for 12 hours, grind them, and pass through an 80-mesh sieve for later use;

[0036] (2) weighing 36 parts of chestnut resistant starch, 15 parts of yam, 15 parts of coix seeds, and 6 parts of platycodon grandiflorum according to the mass fraction, mixing and sieving;

[0037] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0038] Example 2

[0039] The preparation method of chestnut resistant starch is the same as that in Example 1.

[0040] A hypoglycemic compressed tablet containing chestnut resistant starch, the preparation method of which is as follows:

[0041] (1) Dry chestnut resistant starch, yam, coix seed and platycodon grandiflorum at 50°C for 12 hours, grind them, and pass through an 80-mesh sieve for later use;

[0042] (2) weighing the raw material powders according to the weight ratio of 40 parts of chestnut resistant starch, 16 parts of yam, 16 parts of coix seeds and 8 parts of platycodon, mixing and sieving;

[0043] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0044] Comparative Example 1

[0045] Preparation method of chestnut starch:

[0046] Shell and slice fresh chestnuts → wash and soak → crush and sieve → alkali solution extraction (solid-liquid ratio 1:4g / mL, NaOH solution 0.2g / 100mL) → stand at 4℃ for 12h → repeatedly centrifuge (3500r / min, 10min) → collect precipitate (adjust pH to neutral) → repeatedly centrifuge (3500r / min, 10min) → dry, crush → sieve → chestnut starch.

[0047] A hypoglycemic compressed tablet containing chestnut starch, the preparation method of which is as follows:

[0048] (1) Dry chestnut starch, yam, coix seed and platycodon grandiflorum at 50°C for 12 hours, grind them and pass through an 80-mesh sieve for later use;

[0049] (2) Weigh the raw material powders according to the mass proportions of 40 parts of chestnut starch, 16 parts of yam, 16 parts of coix seeds and 8 parts of platycodon, mix and sieve;

[0050] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0051] Comparative Example 2

[0052] The preparation method of chestnut resistant starch is the same as that in Example 1.

[0053] A hypoglycemic compressed tablet containing chestnut resistant starch, the preparation method of which is as follows:

[0054] (1) Dry chestnut resistant starch, yam, coix seed and platycodon grandiflorum at 50°C for 12 hours, grind them, and pass through an 80-mesh sieve for later use;

[0055] (2) weighing the raw material powders according to the weight ratio of 15 parts of chestnut resistant starch, 16 parts of yam, 16 parts of coix seeds and 8 parts of platycodon, mixing and sieving;

[0056] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0057] Comparative Example 3

[0058] The preparation method of chestnut resistant starch is the same as that in Example 1.

[0059] A hypoglycemic compressed tablet containing chestnut resistant starch, the preparation method of which is as follows:

[0060] (1) Dry chestnut resistant starch and platycodon grandiflorum at 50°C for 12 h, grind them, and pass them through an 80-mesh sieve for later use;

[0061] (2) Weighing the raw material powders according to the mass ratio of 40 parts of chestnut resistant starch and 8 parts of platycodon grandiflorum, mixing and sieving;

[0062] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0063] Comparative Example 4

[0064] The preparation method of chestnut resistant starch is the same as that in Example 1.

[0065] A hypoglycemic compressed tablet containing chestnut resistant starch, the preparation method of which is as follows:

[0066] (1) Dry chestnut resistant starch, Chinese yam and Platycodon grandiflorum at 50° C. for 12 h, grind them, and pass them through an 80-mesh sieve for later use;

[0067] (2) weighing 40 parts of chestnut resistant starch, 16 parts of yam and 8 parts of platycodon grandiflorum according to the mass ratio, mixing and sieving;

[0068] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0069] Comparative Example 5

[0070] The preparation method of chestnut resistant starch is the same as that in Example 1.

[0071] A hypoglycemic compressed tablet containing chestnut resistant starch, the preparation method of which is as follows:

[0072] (1) Dry chestnut resistant starch, coix seeds and platycodon grandiflorum at 50°C for 12 h, grind them, and pass through an 80-mesh sieve for later use;

[0073] (2) weighing 40 parts of chestnut resistant starch, 16 parts of coix seeds, and 8 parts of platycodon grandiflorum powder according to their weight percentage, mixing them, and then sieving;

[0074] (3) The mixed raw material powders were put into a tablet press and compressed using a circular die with a diameter of 10 mm. The pressure and thickness were constant and the tablets weighed 0.36 g.

[0075] Experiment 1

[0076] Experimental study on the effect of fasting blood sugar on type Ⅱ diabetes model mice

[0077] C57BL / 6J mice were used to establish a model with a high-fat and high-sugar diet combined with streptozotocin injection, and fasting blood glucose concentration was measured. Mice with successful hyperglycemia modeling (blood glucose values ​​between 11.5 and 25 mmol / L) were selected and divided into 6 groups, with 5 mice in each group. The gavage conditions of each group were as follows:

[0078] The Example 1 group, the Example 2 group and the Comparative Example 1 group were intragastrically administered with the compressed tablets prepared in Example 1, Example 2 and Comparative Example 1, respectively, with an intragastrically administered dose of 5.0 g / kg·bw;

[0079] The positive control group was gavaged with metformin hydrochloride at a dose of 150 mg / kg·bw;

[0080] The model group (type Ⅱ diabetes model mice) and the blank group were gavaged with the same volume of distilled water;

[0081] Once a day for 42 consecutive days, measure FBG values ​​every 14 days.

[0082] The results are shown in Table 1.

[0083] Table 1 Effects of each group on FBG in type Ⅱ diabetic model mice

[0084]

[0085] Note: # represents P<0.05 compared with the model group; ## represents P<0.01 compared with the model group.

[0086] As can be seen from Table 1, the FBG level of mice in the model group was increased, which was significantly different from that in the blank group (P<0.01). From 14d to 42d of intervention, the FBG level of each group was significantly reduced compared with the model group (P<0.01), and the degree of reduction in the embodiment group was higher than that in the control group 1, indicating that the tableting effect of the chestnut resistant starch composition is better than that of the chestnut starch composition, and can effectively control the increase of FBG, and has good potential for treating diabetes.

[0087] Experiment 2

[0088] Oral glucose tolerance test (OGTT) experiment in type 2 diabetes model mice

[0089] The method of modeling and oral gavage treatment of type Ⅱ diabetes mice were the same as those in Experiment 1. After 6 weeks of oral gavage treatment, the fasting blood glucose value was measured after fasting for 12 hours, and then 2.0 g / kg·bw of glucose was gavaged. The fasting blood glucose values ​​of each group at 0, 0.5, and 2.0 hours after glucose administration were measured and the area under the curve was calculated. The experimental results are shown in Table 2.

[0090] Table 2 Effects of each group on OGTT in type Ⅱ diabetic model mice

[0091]

[0092]

[0093] Note: # represents P<0.05 compared with the model group; ## represents P<0.01 compared with the model group.

[0094] As can be seen from Table 2, the glucose tolerance of the model group mice increased, which was significantly different from that of the blank group mice (P<0.01), and the embodiment group was significantly lower than the model group (P<0.01). The blood glucose values ​​and areas under the blood glucose curve of each group of mice at each time point after glucose administration were lower than those of the model group, indicating that the chestnut resistant starch composition tablet can not only effectively reduce the FBG level of type Ⅱ diabetic mice, but also significantly improve the mouse body's tolerance to glucose.

[0095] Experiment 3

[0096] In vitro hypoglycemic experiment

[0097] The glucose adsorption capacity (GAC) of the compressed tablets prepared in Example 2 and Comparative Example 2 was compared. The results are shown in Table 3.

[0098] Table 3 Glucose adsorption capacity results

[0099]

[0100] The in vitro hypoglycemic property is mainly reflected in GAC, which reflects the inhibitory effect on the diffusion and absorption of glucose, and is of great significance for controlling the postprandial blood sugar increase in diabetic patients. As shown in Table 3, after changing the ratio of tableting raw materials, the glucose adsorption capacity decreased significantly.

[0101] Experiment 4

[0102] Experiment on the promotion of hypoglycemic effect of chestnut resistant starch by various components

[0103] The modeling method and gavage treatment of type Ⅱ diabetes model mice were the same as those of experiment 1, once a day for 42 consecutive days, and the FBG value was measured every 14 days. No positive control group was set. The groups were divided into Example 2 group, Comparative Example 3 group, Comparative Example 4 group and Comparative Example 5 group. The effects of each group on FBG of type Ⅱ diabetes model mice are shown in Table 4.

[0104] Table 4 Effects of each group on FBG in type Ⅱ diabetic model mice

[0105]

[0106] Note: # represents P<0.05 compared with the model group; ## represents P<0.01 compared with the model group.

[0107] As can be seen from Table 4, the hypoglycemic effect of the group without adding yam, coix seed and neither component is added is weaker than that of the group in Example 2, indicating that the addition of each component has a promoting effect on the hypoglycemic effect of chestnut resistant starch. It also shows that both yam and coix seed are indispensable in the composition of the present invention, and the two act synergistically with chestnut resistant starch and platycodon to achieve a hypoglycemic effect.

[0108] In summary, the chestnut resistant starch composition tablet provided by the present invention has the following characteristics:

[0109] (1) The chestnut resistant starch composition provided by the present invention has significant in vivo hypoglycemic activity when pressed into tablets, and can be applied in the fields of medicine and health food to promote the high-value utilization of chestnuts.

[0110] (2) The preparation process does not introduce toxic and harmful substances, conforms to the food-grade extraction process, and has the characteristics of green environmental protection. The overall preparation process of the chestnut resistant starch composition tablet is simple to operate, has good controllability and low cost, and has good application prospects and commercial feasibility.

[0111] In this specification, each embodiment is described in a progressive manner, and each embodiment focuses on the differences from other embodiments, and the same and similar parts between the embodiments can be referred to each other. The above description of the disclosed embodiments enables professionals and technicians in this field to implement or use the present invention. Various modifications to these embodiments will be obvious to professionals and technicians in this field, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to these embodiments shown in this article, but will comply with the widest range consistent with the principles and novel features disclosed herein.

Claims

1. A hypoglycemic composition containing chestnut resistant starch, characterized in that: The invention comprises the following components in parts by weight: 30-40 parts of chestnut resistant starch, 10-20 parts of yam, 10-20 parts of coix seeds and 2-10 parts of platycodon.

2. The composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 36-40 parts of chestnut resistant starch, 15-16 parts of yam, 15-16 parts of coix seeds and 6-8 parts of platycodon grandiflorum.

3. The composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 36 parts of chestnut resistant starch, 15 parts of yam, 15 parts of coix seeds and 6 parts of platycodon grandiflorum.

4. The composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 40 parts of chestnut resistant starch, 16 parts of yam, 16 parts of coix seeds and 8 parts of platycodon grandiflorum.

5. The composition according to claim 1, characterized in that The chestnut resistant starch accounts for ≥40% of the total mass ratio, and the total amount of yam and coix seed accounts for ≥10% of the total mass ratio.

6. The method for preparing the composition according to any one of claims 1 to 5, characterized in that: The method comprises the following steps: drying, crushing, sieving, mixing and sieving the raw materials, and pressing the raw materials with a tablet press.

7. The preparation method according to claim 6, characterized in that: The sieving is through an 80-mesh sieve.

8. The preparation method according to claim 6, characterized in that: The specific operation of the tablet press is: using a circular mold with a diameter of 10 mm, keeping the pressure and thickness constant, and pressing in the tablet press, the tablet weight is 0.36 g.

9. Use of the composition according to any one of claims 1 to 5 in the preparation of hypoglycemic drugs.

Images